A baby formula maker’s ‘bizarre’ response to the infant botulism outbreak
ByHeart made headlines this week when it issued a nationwide recall of all its products in the U.S. This decision came after 15 infants were hospitalized due to botulism after consuming ByHeart’s formula. Despite clear evidence linking the formula to the illness, the company initially resisted the regulators’ findings in their response to the recall. This led to backlash from customers who accused the company of downplaying, burying information, and misleading parents throughout the process.
With a hefty $908 million in venture capital backing, ByHeart burst onto the market in 2016, offering a formula touted as rich in “clean ingredients” and targeted towards health-conscious mothers. The formula also gained popularity within the Make America Healthy Again movement. However, ByHeart’s track record raises concerns, including a previous recall in 2022 and a warning letter from the FDA following an inspection the following year.
For more insights into ByHeart’s questionable response to the infant botulism outbreak and the implications of the nationwide recall, check out STAT’s Sarah Todd’s in-depth coverage.
More Americans use weight loss drugs like Ozempic than live in Texas
The prevalence of weight loss drugs, particularly GLP-1 medications like Ozempic and Wegovy, has surged in recent years. According to a recent KFF poll on GLP-1 drugs and drug prices, nearly 13% of adults reported using a GLP-1 drug for chronic disease management, weight loss, or both. This figure represents more than double the percentage reported in the previous year.
Despite the high cost of these medications, with nearly 30% of users bearing the full financial burden even with health insurance, their popularity continues to rise. The poll’s release coincided with a recent deal announced by former President Trump aimed at making these drugs more affordable for the general population.
To delve deeper into the rising use of GLP-1 drugs, their impact on weight management, and the implications of Trump’s initiative to make them more accessible, explore the latest findings and insights.
Wild polio, continued
Recent developments have shed light on the discovery of wild poliovirus in wastewater in Germany. Authorities in Hamburg disclosed that Type 1 poliovirus was detected in sewage, with the genetic sequence closely resembling strains found in Afghanistan, one of the last two countries where wild polioviruses are endemic.
The Robert Koch Institute reported that the virus likely originated from an infected individual excreting the virus in stool while in Hamburg. While no symptomatic cases have been reported, the risk of transmission remains a concern. However, high polio vaccination rates in Germany have minimized the risk of further spread and subsequent cases.
For more details on the wild polio discovery in Germany, the potential implications, and ongoing efforts to prevent the spread of the virus, read the latest update from the Robert Koch Institute.
Former FDA commissioner talks new drug director, building trust
Former FDA commissioner Robert Califf recently engaged in a discussion about trust and medical ethics, particularly in light of the appointment of Richard Pazdur as the FDA’s top drug regulator. Califf commended Pazdur for his integrity and commitment to ethical decision-making, emphasizing the importance of aligning beliefs with actions in leadership roles.
Califf also expressed concerns about the increasing influence of politics on science within U.S. health agencies and the need to rebuild trust with the American public. Drawing parallels to social media influencers like Mr. Beast, Califf highlighted the role of influential figures in shaping public behavior and perceptions.
To learn more about Califf’s insights on the FDA leadership transition, the challenges of restoring trust in healthcare, and the impact of influential personalities on public health, dive into the details of his recent discussion.
Precision medicine — but for psychiatry
The landscape of mental health treatments is evolving, with a shift towards precision medicine in psychiatry. Unlike traditional approaches that rely on broad-spectrum drugs, new treatments are targeting specific pathways and receptors associated with conditions like schizophrenia. This precision approach offers promising advancements in drug development and personalized care for mental health patients.
With updated FDA guidelines reshaping the drug development process, investors, insurers, and the healthcare economy are poised to experience significant changes. Khutaija Noor, a leading expert in psychiatric medicine, explores the implications of this shift and the potential benefits for patients and stakeholders in the mental health sector.
To learn more about the emerging trends in precision medicine for psychiatry, the impact on treatment outcomes, and the future of mental health care, delve into the latest insights from industry experts.
What we’re reading
– Life in beige, The Cut
– US bishops officially ban gender-affirming care at Catholic hospitals, AP
– Going against the gut: Q&A with Kevin Mitchell on the autism-microbiome theory, The Transmitter
– Republicans want to replace enhanced ACA tax credits with direct payments, STAT
Stay informed with the latest news and insights from reputable sources across various healthcare topics and policy developments.
